CXCL9

Chr 4

C-X-C motif chemokine ligand 9

Also known as: CMK, Humig, MIG, SCYB9, crg-10

NCBI Gene: 4283 ENSG00000138755 UniProt: Q07325

The encoded protein is a chemokine that functions as a chemoattractant for activated T cells and binds to the CXCR3 receptor, playing a role in immune and inflammatory responses. Mutations in this gene are associated with neurological disorders, though this gene shows low constraint to loss-of-function variation (pLI = 0.003, LOEUF = 1.69). A GeneReviews entry is available for detailed clinical information about associated conditions and inheritance patterns.

GeneReviews ResearchSummary from RefSeq, UniProt

This antimicrobial gene is part of a chemokine superfamily that encodes secreted proteins involved in immunoregulatory and inflammatory processes. The protein encoded is thought to be involved in T cell trafficking. The encoded protein binds to C-X-C motif chemokine 3 and is a chemoattractant for lymphocytes but not for neutrophils. [provided by RefSeq, Aug 2020]

GeneReviews ResearchGenerating clinical summary…

Active trials

790

Pubs (1 yr)

—

P/LP submissions

—

P/LP missense

1.69

LOEUF

Mechanism· predicted

📖

GeneReview available — CXCL9

Authoritative clinical overview · Recommended first read

Open GeneReview ↗

Some data sources returned errors (1)

omim: Error: OMIM fetch failed: 429

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

gnomAD

Tolerant — LoF & missense variants common in population

LoF Constraint?

1.69LOEUF

pLI 0.003

Z-score 0.40

OE 0.81 (0.39–1.69)

Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?

-0.03Z-score

OE missense 1.01 (0.83–1.24)

66 obs / 65.3 exp

Tolerant

Tolerant to missense variation

Observed / Expected Ratios?

LoF OE?0.81 (0.39–1.69)

0≤0.351.4

Missense OE?1.01 (0.83–1.24)

0≤0.61.4

Synonymous OE?1.20

0≤1.21.6

LoF obs/exp: 4 / 5.0Missense obs/exp: 66 / 65.3Syn Z: -0.72

ClinVar Variant Classifications

0 submitted variants in ClinVar

ClinVar

Protein Context — Lollipop Plot

CXCL9 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

External Resources

Links to major genomics databases and tools

Franklin by Genoox

AI-powered variant curation and clinical analysis

DECIPHER

Genomic variants and phenotypes in rare disease patients

📖

GeneReview available — CXCL9

Authoritative clinical overview · NCBI Bookshelf · Recommended first read

Open GeneReview ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

ClinicalTrials.gov

MetforminAging

Pilot Study on Evaluating the Geroprotective Effect of Metformin

RECRUITING

NCT06459310Phase PHASE2Xuanwu Hospital, BeijingStarted 2024-06-30

Metformin Hydrochloride tabletPlacebo

Kidney TransplantRejection

Detection of Circulating Kidney DNA in Kidney Transplant Patients Facing an Episode of Graft Rejection

RECRUITING

NCT06351488Assistance Publique - Hôpitaux de ParisStarted 2024-08-21

Rejection; Transplant, Liver

Transcriptomics as an Aid in the Histological Diagnosis of Acute Rejection After Liver Transplantation

RECRUITING

NCT06734013Phase NAIRCCS Azienda Ospedaliero-Universitaria di BolognaStarted 2024-10-17

Molecular diagnostic

Central Centrifugal Cicatricial AlopeciaFrontal Fibrosing Alopecia

Deucravacitinib in the Treatment of Cicatricial Alopecias

RECRUITING

NCT07508488Phase PHASE2Icahn School of Medicine at Mount SinaiStarted 2026-05-28

Deucravacitinib

Glioma

The Role of B7-H4 in Tumor Vaccine

RECRUITING

NCT06156150Huashan HospitalStarted 2023-11-26

tumor vaccine

Breast NeoplasmTriple Negative Breast Cancer (TNBC)HRD

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer

RECRUITING

NCT03740893Phase PHASE2Institute of Cancer Research, United KingdomStarted 2019-10-15

AZD6738OlaparibDurvalumab

Cutaneous Squamous Cell Carcinoma (CSCC)

Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.

RECRUITING

NCT07064330Instituto de Investigación Biomédica de SalamancaStarted 2025-07-17

Cemiplimab

Hepatitis

Severe Hepatitis Intervention With Emapalumab for Liver Disease

NOT YET RECRUITING

NCT07744919Phase PHASE2Children's Healthcare of AtlantaStarted 2026-09-01